Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Atezolizumab boosts outcomes in squamous NSCLC

Jotte et al. ASCO 2018 Abstract LBA9000.

Key clinical point: Adding atezolizumab to first-line chemotherapy for squamous NSCLC improves outcomes.

Major finding: Compared with chemotherapy alone, chemotherapy plus atezolizumab prolonged median progression-free survival from 5.6 to 6.3 months (hazard ratio, 0.71; P = .0001).

Study details: A phase 3 randomized, controlled trial among 1,021 all-comer (PD-L1–unselected), chemotherapy-naïve patients with stage IV squamous NSCLC (IMpower131 trial).

Disclosures: Dr. Jotte disclosed that he is on the speakers’ bureau for Bristol-Myers Squibb, and that he receives travel, accommodations, and/or expenses, as well as honoraria from Bristol-Myers Squibb. The study received funding from F. Hoffmann-La Roche Ltd.

Source: Jotte et al. ASCO 2018 Abstract LBA9000.

Read the article.


Jotte et al. ASCO 2018 Abstract LBA9000.

This Week's Must Reads

CMS freezing of risk adjustment payments predicted to drive up insurance premiums, United States District Court Ruling Puts Risk Adjustment On Hold

If confirmed as Supreme Court justice, Kavanaugh could upend ACA, Case references, including Seven-Sky v. Holder

Software boosts accuracy of colonoscopies, Tripathi PV et al. DDW 2018 (Digestive Disease Week, 2018). Presentation 133.

Proposed fee schedule for 2019 could cut EHR hours,

Must Reads in Lung Cancer

Atezolizumab boosts outcomes in squamous NSCLC, Jotte et al. ASCO 2018 Abstract LBA9000.

CT scans underused for lung cancer screens, Pham DC et al. ASCO 2018. Abstract 6504.

Brain met outcomes similar for NSCLC, breast cancer patients, Cagney DN et al. JAMA Oncol. 2018 May 17. doi: 10.1001/jamaoncol.2018.0813.

Health Disparities in Elderly with NSCLC Studied, Cancer; ePub 2018 Jan 8; Cassidy, Zhang, et al

Barriers to Combo Therapy for Limited-Stage SCLC , JAMA Oncol; ePub 2018 Jan 4; Pezzi, et al